港股异动 | 荣昌生物(09995)涨超6% 25年股东应占利润7.09亿元机构料其现金储备显著增加

智通财经03-06

智通财经APP获悉，荣昌生物(09995)涨超6%，截至发稿，涨6.44%，报81.75港元，成交额1.7亿港元。消息面上，近日，荣昌生物发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%；归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈；基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2617505041?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-06 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617505041","market":"hk","top_or_hot":-1,"title":"港股异动 | 荣昌生物(09995)涨超6% 25年股东应占利润7.09亿元 机构料其现金储备显著增加","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，荣昌生物(09995)涨超6%，截至发稿，涨6.44%，报81.75港元，成交额1.7亿港元。消息面上，近日，荣昌生物发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%；归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈；基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410810.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 荣昌生物(09995)涨超6% 25年股东应占利润7.09亿元 机构料其现金储备显著增加</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 荣昌生物(09995)涨超6% 25年股东应占利润7.09亿元 机构料其现金储备显著增加\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-06 10:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1410810.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，荣昌生物(09995)涨超6%，截至发稿，涨6.44%，报81.75港元，成交额1.7亿港元。消息面上，近日，荣昌生物发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%；归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈；基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410810.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064130708.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1410810.html","article_id":"2617505041","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617505041","pubTimestamp":1772763627,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，荣昌生物涨超6%，截至发稿，涨6.44%，报81.75港元，成交额1.7亿港元。消息面上，近日，荣昌生物发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%；归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈；基本每股收益人民币1.29元。因现金储备显著增加，公司营运支出将按年升28%至35亿元人民币，扭转去年成本节约趋势。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","BK1574":"生物医药B类股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","09995":"荣昌生物","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VT":"世界全股市ETF-Vanguard","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"Changes in Hong Kong stocks | Rongchang Biotech (09995) rose by more than 6%. Profit attributable to shareholders in 25 years was 709 million yuan. Institutions expected their cash reserves to increase significantly","themeId":"5137f1e9d165d819bc52e4abac894dbc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1.5,"VXUS":1.5,"VT":1.5,"09995":1.5},"content_text":"智通财经APP获悉，荣昌生物(09995)涨超6%，截至发稿，涨6.44%，报81.75港元，成交额1.7亿港元。消息面上，近日，荣昌生物发布2025年度业绩快报，该公司取得营业总收入人民币32.51亿元，同比增加89.36%；归属于母公司所有者的净利润人民币7.09亿元，同比扭亏为盈；基本每股收益人民币1.29元。公告称，营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加；此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术授权收入大幅增加。野村发布研报预测，料荣昌生物今年毛利率按年升5.4个百分点至94.4%，主要受惠药品毛利率提升及高毛利合作收入占比增加。因现金储备显著增加，公司营运支出将按年升28%至35亿元人民币，扭转去年成本节约趋势。具体而言，研发支出与销售费用料各为16亿元人民币，用于赞助新分子研发与临床试验，以及提升药物销售。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617505041","isCrawlerRequest":true}

港股异动 | 荣昌生物(09995)涨超6% 25年股东应占利润7.09亿元 机构料其现金储备显著增加

精彩评论

港股异动 | 荣昌生物(09995)涨超6% 25年股东应占利润7.09亿元机构料其现金储备显著增加